Publications by authors named "Timothy C Horan"
Article Synopsis
- The study aimed to explore the effectiveness of 3-indolylmethanamines 31B and PS121912 in treating ovarian cancer and leukemia, respectively.
- Various methods, including TUNEL and western blotting, were used to analyze apoptosis and tumor growth in mice models.
- The results indicated that compound 31B successfully inhibited ovarian cancer cell proliferation and tumor growth without toxicity, while also impacting glucose metabolism, highlighting the potential of 3-indolylmethanamines as a new class of antitumor agents.
Hypercalcemia remains a major impediment to the clinical use of vitamin D in cancer treatment. Approaches to remove hypercalcemia and development of nonhypercalcemic agents can lead to the development of vitamin D-based therapies for treatment of various cancers. In this report, in vitro and in vivo anticancer efficacy, safety, and details of vitamin D receptor (VDR) interactions of PT19c, a novel nonhypercalcemic vitamin D derived anticancer agent, are described.
View Article and Find Full Text PDFArticle Synopsis
- The study explores the potential of 7 Methyl-indole ethyl isothiocyanate (7Me-IEITC) as a treatment for advanced endometrial cancer, highlighting the need for new therapies.
- 7Me-IEITC was found to significantly reduce the viability of endometrial cancer cell lines (ECC-1 and KLE) through mechanisms involving apoptosis and mitochondrial dysfunction.
- The compound's effect was linked to oxidative stress and specific changes in protein expression, indicating its cytotoxicity may be primarily due to ROS production, suggesting further research is warranted.
Background: Numerous vitamin-D analogs exhibited poor response rates, high systemic toxicities and hypercalcemia in human trials to treat cancer. We identified the first non-hypercalcemic anti-cancer vitamin D analog MT19c by altering the A-ring of ergocalciferol. This study describes the therapeutic efficacy and mechanism of action of MT19c in both in vitro and in vivo models.
View Article and Find Full Text PDFArticle Synopsis
- This study explores the effectiveness of new compounds, adamantyl-N-acetylcystein and adamantyl isothiocyanate, in treating gynecological cancers, showing they can kill cancer cells in lab tests.
- The compounds were found to halt the cancer cell cycle specifically in SKOV-3 ovarian cancer cells and induced apoptosis, evidenced by DNA fragmentation.
- Adamantyl-N-acetylcystein’s cytotoxic effects rely on increased reactive oxygen species, and future research may enhance its efficacy using signaling inhibitors or antioxidant treatments in real tumor models.
The objective of the present study was to determine the in-vitro effect of Abietyl-Isothiocyanate (ABITC), a representative of a new class of anti-cancer drugs, on endometrial cancer (EC) cell lines. ABITC at concentrations ≥1 μM displayed dose-dependent and selective cytotoxicity to EC cell lines (ECC-1, AN3CA, RL95-2) in comparison to other cancer cell lines. After treatment with ABITC, ECC-1 unlike control cells displayed hallmark features of apoptosis including chromatin condensation and nuclear fragmentation.
View Article and Find Full Text PDF